Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
WARRINGTON, Pa., Windtree Therapeutics, Inc., a diversified company focused on revenue generation
Trump’s push to onshore pharma manufacturing clouded by ‘lack of clarity’
Questions remain as to how FDA inspection differences between domestic and foreign drug facilities will play out.
Gilead hit with FDA clinical hold for batch of HIV trials
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipel...
NHS to receive £29bn funding boost
The UK Government’s new investment includes funding for GP training and a £10bn outlay on technology and digital transformation.
Pancreatic cancer vaccines eliminate disease in preclinical trials
CLEVELAND—Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer Society.
MSD receives FDA approval for Enflonsia to prevent respiratory syncytial virus (RSV)
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in...
Aytu BioPharma to commercialise Exxua for major depressive disorder in the US
Aytu BioPharma to commercialise Exxua for major depressive disorder in the US
Psilera Collaborates with Drug Development Leader Hesperos
Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
Jade Biosciences Presents JADE101
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m
Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic health.
Finerenone plus SGLT2 inhibitor reduces albuminuria more than either drug alone
Concurrent use of finerenone and empagliflozin reduced urine albumin-to-creatinine ratio for adults with CKD and type 2 diabetes.
40
41
42
43
44
45
46
47
48
